Cargando…
Universal Correction of Blood Coagulation Factor VIII in Patient-Derived Induced Pluripotent Stem Cells Using CRISPR/Cas9
Hemophilia A (HA) is caused by genetic mutations in the blood coagulation factor VIII (FVIII) gene. Genome-editing approaches can be used to target the mutated site itself in patient-derived induced pluripotent stem cells (iPSCs). However, these approaches can be hampered by difficulty in preparing...
Autores principales: | Park, Chul-Yong, Sung, Jin Jea, Cho, Sung-Rae, Kim, Jongwan, Kim, Dong-Wook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565751/ https://www.ncbi.nlm.nih.gov/pubmed/31105049 http://dx.doi.org/10.1016/j.stemcr.2019.04.016 |
Ejemplares similares
-
Engineering CRISPR/Cas9 for Multiplexed Recombinant Coagulation Factor Production
por: Feser, Colby J., et al.
Publicado: (2022) -
CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells
por: Kim, Eun Ji, et al.
Publicado: (2017) -
Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology
por: Li, Lingli, et al.
Publicado: (2022) -
Endogenous Protein Tagging in Human Induced Pluripotent Stem Cells Using CRISPR/Cas9
por: Haupt, Amanda, et al.
Publicado: (2018) -
An Alternate Approach to Generate Induced Pluripotent Stem Cells with Precise CRISPR/Cas9 Tool
por: Javaid, Nasir, et al.
Publicado: (2022)